Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


The next generation of DNMT inhibitors

DNA methyltransferase inhibitors are widely used in preclinical and clinical studies, but poor pharmacokinetics and low efficacy in solid tumors limit their therapeutic use. A new study reports the development and characterization of a specific, non-covalent DNA methyltransferase inhibitor with more-durable DNA hypomethylation and lower toxicity than that of nucleoside analogs.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mechanism of DNMT1 inhibition by GSK3685032 versus that of AZA and DAC.


  1. Jones, P. A. & Liang, G. Nat. Rev. Genet. 10, 805–811 (2009).

    Article  CAS  Google Scholar 

  2. Roulois, D. et al. Cell 162, 961–973 (2015).

    Article  CAS  Google Scholar 

  3. Chiappinelli, K. B. et al. Cell 162, 974–986 (2015).

    Article  CAS  Google Scholar 

  4. Pappalardi, M. B. et al. Nat. Cancer (2021).

  5. Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Nature 429, 457–463 (2004).

    Article  CAS  Google Scholar 

  6. Mehdipour, P., Murphy, T. & De Carvalho, D. D. Pharmacol. Ther. 205, 107416 (2020).

    Article  CAS  Google Scholar 

  7. Mehdipour, P. et al. Nature 588, 169–173 (2020).

    Article  CAS  Google Scholar 

  8. Loo Yau, H. et al. Mol. Cell 81, 1469–1483.e8 (2021).

    Article  CAS  Google Scholar 

  9. Fresquet, V. et al. Cancer Discov. 11, 1268–1285 (2021).

    Article  CAS  Google Scholar 

  10. Derissen, E. J. B., Beijnen, J. H. & Schellens, J. H. M. Oncologist 18, 619–624 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Daniel D. De Carvalho.

Ethics declarations

Competing interests

D.D.D.C. received research funds from Pfizer and Nektar Therapeutics, and is co-founder and chief scientific officer at Adela.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mehdipour, P., Chen, R. & De Carvalho, D.D. The next generation of DNMT inhibitors. Nat Cancer 2, 1000–1001 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research